Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
| ▸ | EED | O75530 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.73 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.73 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.73 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18400601 | 0.93 | EZH2 (0.80) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL23030040 | 0.90 | EZH2 (0.72) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL23462987 | 0.90 | EZH2 (0.83) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL13276603 | 0.89 | EZH2 (0.78) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL24239037 | 0.87 | EZH2 (0.70) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL13277378 | 0.87 | EZH2 (0.93) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL13277474 | 0.87 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL19570165 | 0.86 | EZH2 (0.67) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL13277046 | 0.86 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL17026101 | 0.86 | EZH2 (0.67) | EZH2NR1I2EEDABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301290-B2 | Combination therapy for treating cancer | Epizyme, Inc. (US) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301290-B2 | Combination therapy for treating cancer | EZH2, BMI1, HDAC2 | EZH2 1/4885NR1I2 2153/4885EED 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.